A. M. Traynor, M. Hewitt, G. Liu, K. T. Flaherty, J. Clark, S. J. Freedman, B. B. Scott, A. M. Leighton, P. A. Watson, B. Zhao, P. J. O’Dwyer and G. Wilding, “Phase I Dose Escalation Study of MK-0457, a Novel Aurora Kinase Inhibitor, in Adult Patients with Advanced Solid Tumors,” Cancer Chemotherapy and Pharmacology, Vol. 67, No. 2, 2011, pp. 305-314. doi:10.1007/s00280-010-1318-9

has been cited by the following article:

• TITLE: Evaluation of the Aurora Kinase Inhibitor, ZM447439, in Canine Malignant Lymphoid Cells in Vitro

  AUTHORS: Keijiro Shiomitsu, Xueqing Xia, Kyle Waite, Inder Sehgal, Shulin Li

  KEYWORDS: Aurora Kinase Inhibitor; Canine Malignant Lymphoid Cells; Cell Cycle; Apoptosis; ZM447439

  JOURNAL NAME: Open Journal of Veterinary Medicine, Vol.3 No.1, March 21, 2013

  ABSTRACT: Aurora kinases play an important role in the cell cycle. These enzymes help establish mitotic spindles by directing centrosome duplication and separation and by regulating the spindle assembly checkpoint thereby helping control cytokinesis. An over-expression of aurora kinases has been reported in a variety of human tumors. In this study, we identified the expression of aurora-A and aurora-B kinases in canine malignant lymphoid cells. We also evaluated the effects of the aurora kinase inhibitor (ZM447439), and found that this inhibitor decreases cell viability, increases DNA content change, and leads to apoptosis in canine B- and T-cell lymphoid cell lines. The lymphotoxicity induced by ZM447439 in these canine lymphoid cell lines suggests that further in vivo evaluation of aurora kinase inhibitors as a potential treatment for canine malignant lymphoid tumors is warranted.